ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 379

Risk Factors of Venous Thromboembolism in Idiopathic Inflammatory Myopathies

Julien Campagne1, Thomas Moulinet2, Jonathan Epstein3, Sabine Revuz4, Francois Maurier5, Marie-Hélène Schuhmacher6, Philippe Evon7, Alain Meyer8 and Roland Jaussaud2, 1Médecine Interne, Centre Hospitalier Régional Universitaire de Nancy, Vandoeuvre-lès-Nancy, France, 2Médecine Interne, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France, 3Inserm, CIC-1433 Epidémiologie Clinique, Vandoeuvre-lès-Nancy, France, 4Médecine Interne, Hôpitaux Privés de Metz, Metz, France, 5Médecine interne, Hôpitaux Privés de Metz, Metz, France, 6Médecine Interne, Centre Hospitalier Emile Durkheim, Epinal, France, 7Médecine Interne, Centre Hospitalier Jeanne d'Arc, Bar-le-Duc, France, 8Médecine Interne, Centre Hospitalier Régional Universitaire de Strasbourg, Strasbourg, France

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: dermatomyositis, Myositis, polymyositis, risk and thrombosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Muscle Biology, Myositis and Myopathies Poster I: Clinical Features and Disease Course

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Idiopathic inflammatory myopathies (IIM) are heterogeneous disorders characterised by skeletal muscle weakness and muscle inflammation. IIM includes dermatomyositis (DM), polymyositis (PM), antisynthetase syndromes (ASS), scleromyositis (SCM), inclusion body myositis (IBM), immune-mediated necrotizing myopathies (IMNM) and Overlap Syndromes (OS). Previous population-based studies have demonstrated a higher risk of venous thromboembolism (VTE) in IIM patients compared to healthy controls. In these works, IIM were only divided in PM and DM and few risk factors of VTE have been highlighted. The purpose of this study was to identify the VTE specific risk factors in IIM and analyse VTE occurrence in more recently defined subtypes of IIM.

Methods: All adults with IIM hospitalized in Internal Medicine units from Eastern France between 2004 and 2018 were enrolled. Demographic, clinical and laboratory data were retrospectively collected from medical records. Mann-Whitney test and Chi-square test were used for comparison of continuous and discrete variables, respectively. We computed a multivariate model to determine factors associated with VTE using a Cox analysis. VTE-free survival analysis was performed using log-rank test.

Results: 203 patients (55 male, 148 female) were involved. The mean age at diagnosis was 51 years +/-16. VTE occurred in 12% of cases, mostly within the first year of follow-up (31%). At VTE diagnosis, conditions such as immobilization (20%), infection (10%), malignancy (20%), active disease (31%), treatment by intravenous immunoglobulins (17%) or by glucocorticoids (55%) were observed. In univariate analysis, we found that patients with VTE experienced more dysphonia (p=0.037) and received a greater number of therapeutic lines (p=0.035) compared to patients without VTE. In multivariate analysis, significant risk factors were personal history of pulmonary embolism (HR 13, p=0.023), dysphonia (HR 99, p=0,00005), elevated C-reactive protein (HR 5.1, p=0.0081) and number of therapeutic lines (HR 2.7, p=0.023). We compared VTE-free survival in all IIM subtypes within the five years after diagnosis: a particular subgroup including DM, PM, ASS, OS and IMNM (group 1) presented a higher risk than another including SCM, IBM and unspecified myositis (group 2) (HR 4.21, p=0,048).

Conclusion: Common but also unexpected risk factors were reported here. Elevated C-reactive protein confirmed the link between inflammation and thrombosis mechanisms. Dysphonia and the number of therapeutic lines reflected a more severe disease. Among IIM, only those in group 1 (DM, PM, ASS, OS and IMNM) were associated with an increased risk of VTE. The identification of these subtypes should alert to VTE risk and lead to early apply prophylactic measures.


Disclosure: J. Campagne, None; T. Moulinet, None; J. Epstein, None; S. Revuz, None; F. Maurier, None; M. H. Schuhmacher, None; P. Evon, None; A. Meyer, None; R. Jaussaud, None.

To cite this abstract in AMA style:

Campagne J, Moulinet T, Epstein J, Revuz S, Maurier F, Schuhmacher MH, Evon P, Meyer A, Jaussaud R. Risk Factors of Venous Thromboembolism in Idiopathic Inflammatory Myopathies [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/risk-factors-of-venous-thromboembolism-in-idiopathic-inflammatory-myopathies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-factors-of-venous-thromboembolism-in-idiopathic-inflammatory-myopathies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology